https://scholars.lib.ntu.edu.tw/handle/123456789/519468
標題: | From mild cognitive impairment to subjective cognitive decline: Conceptual and methodological evolution | 作者: | Cheng Y.-W. TA-FU CHEN MING-JANG CHIU |
公開日期: | 2017 | 出版社: | Dove Medical Press Ltd. | 卷: | 13 | 起(迄)頁: | 491-498 | 來源出版物: | Neuropsychiatric Disease and Treatment | 摘要: | Identification of subjects at the early stages of Alzheimer’s disease (AD) is fundamental for drug development and possible intervention or prevention of cognitive decline. The concept of mild cognitive impairment (MCI) evolved during the past two decades to define subjects at the transitional stage between normal aging and dementia. Evidence from cross-sectional and longitudinal studies has shown that MCI is associated with an increased risk of positive AD biomarkers and an increased annual conversion rate of 5%–17% to AD. The presence of AD biomarkers in subjects with MCI was associated with an even higher risk of progression to dementia. However, earlier clinical trials for pharmacotherapy in subjects with MCI were disappointing. To extend the spectrum of AD to an earlier stage before MCI, subjective cognitive decline (SCD) was introduced and was defined as self-reported cognitive decline before the deficits could be detected by cognitive tests. Subjects with SCD have an increased risk of underlying AD pathology. However, SCD can also develop secondary to other heterogeneous etiologies, including other neurodegenerative and psychiatric diseases, personality traits, physical conditions, and medication use. Several clinical and biomarker features were proposed to predict risk of conversion to AD in subjects with SCD. Further longitudinal studies are needed to support the validity of these high-risk features. ? 2017 Cheng et al. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85013377303&doi=10.2147%2fNDT.S123428&partnerID=40&md5=851ef095d5347bb27047351532269293 https://scholars.lib.ntu.edu.tw/handle/123456789/519468 |
ISSN: | 1176-6328 | DOI: | 10.2147/NDT.S123428 | SDG/關鍵字: | amyloid beta protein[1-42]; apolipoprotein E4; biological marker; memantine; tau protein; Alzheimer disease; brain atrophy; cognition assessment; dementia; disease association; disease classification; disease course; human; mental deterioration; mental disease; mild cognitive impairment; neurologic examination; personality; prevalence; protein function; psychopathy; Review; risk assessment; risk factor |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。